2024-07-23 08:59:02 ET
DENVER, Colo., Jul 23, 2024 ( 247marketnews.com )- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL ) stated the progression to the second cohort in the pharmacokinetics study of AD04, following the successful completion of the first cohort of the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD). Topline results from both cohorts are expected to be announced later this year.
Adial’s President and CEO, Cary Claiborne, stated, “We are pleased with the progress of our pharmacokinetics study of AD04. The successful completion of the first cohort allows us to advance to the second cohort as planned, staying on track with our projected timeline. The results from both cohorts will offer invaluable insights that are critical for the design of our upcoming Phase 3 Clinical Trial. We anticipate engaging with the FDA following receipt of the topline data from this study and seek their feedback on the overall design of our Phase 3 program.”
The post 24/7 Market News- Adial Pharmaceuticals AD04 Advances to Second Cohort in Pharmacokinetics Study for the Treatment of AUD appeared first on 24/7 MarketNews .
For further details see:
24/7 Market News- Adial Pharmaceuticals AD04 Advances to Second Cohort in Pharmacokinetics Study for the Treatment of AUD